Table 1.
Conclusions from Analysis of Neratinib in ERBB-Mutant Tumors in Context of Trial Status
| Status in Simon Optimal 2-Stage Design |
Responses Significantly Different from Other Tumorsa? |
||||
|---|---|---|---|---|---|
| Tumor Type | Number of Patients | Stage 1 | Stage 2 | Volume | PFS |
| Ovarian | 4 | ongoing | – | – | – |
| Gastroesophageal | 5 | ongoing | – | – | – |
| Colorectal | 12 | failed | – | – | – |
| Bladder | 16 | failed | – | – | – |
| Endometrial | 7 | failed | – | – | – |
| Biliary | 9 | passed | ongoing | superior | – |
| Cervical | 5 | passed | ongoing | superior | superior |
| Lung | 26 | passed | failed | superior | superior |
| Breast | 25 | passed | passed | superior | – |
a
Dash denotes no significant difference by Benjamini-Hochberg procedure.